Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | The role of protein dynamics and proteolysis in light chain amyloid aggregation

Stefano Ricagno • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Stefano Ricagno, PhD, University of Milan, Milan, Italy, comments on protein dynamics and proteolysis in light chain amyloid aggregation, highlighting some of the questions remaining in this space. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stefano Ricagno

ISA session highlights: basic research on light chains & cardiotoxicity in amyloidosis
1:56
ISA session highlights: basic research on light chains & cardiotoxicity in amyloidosis
Stefano Ricagno • 6 Sep 2022
What is currently known about AL amyloidosis with cardiac involvement?
1:18
What is currently known about AL amyloidosis with cardiac involvement?
Stefano Ricagno • 6 Sep 2022
An insight into organ dysfunction and damage in AL amyloidosis
1:15
An insight into organ dysfunction and damage in AL amyloidosis
Stefano Ricagno • 6 Sep 2022

Related Videos

How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
The content of VJHemOnc is intended for healthcare professionals